Evidence map›Paper›PMID 41501363›Full record

Observational studyHypertension research : official journal of the Japanese Society of Hypertension2026

Feasibility study protocol for the evaluation of home blood pressure in patients receiving angiogenesis inhibitor therapy: a multicenter observational study.

Kaori Kitaoka, Satoshi Morimoto, Shintaro Minegishi, Hiroshi Kato, Yasuyuki Kitahara, Wataru Shioyama, Taro Shiga, Kazuko Tajiri, Masaaki Shoji, Mitsuhiro Fukata and 5 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kaori KitaokaShiga University of Medical Science, NCD Epidemiology Research Center, Shiga, Japan.
Satoshi MorimotoDepartment of Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. morimoto.satoshi@twmu.ac.jp.
Shintaro MinegishiDepartment of Cardiology, Yokohama City University School of Medicine, Yokohama, Japan.
Hiroshi KatoDivision of Onco-Cardiology, Miyagi Cancer Center, Miyagi, Japan.
Yasuyuki KitaharaDepartment of Cardiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Wataru ShioyamaDepartment of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan.
Taro ShigaDepartment of General Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazuko TajiriDepartment of Cardiology, National Cancer Center Hospital East, Kashiwa, Japan.
Masaaki ShojiDepartment of General Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Mitsuhiro FukataDepartment of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Hiroshi AkazawaDepartment of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mikio MukaiOsaka Center for Cancer and Cardiovascular Disease Prevention, Osaka, Japan.
Yuichiro YanoDepartment of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.
Akira NishiyamaDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated blood pressure is frequently observed during cancer treatment with vascular endothelial growth factor inhibitors, reflecting either a treatment-emergent adverse event or pharmacological effect. Appropriate blood pressure management is critical in minimizing cardiovascular risk and prevent treatment interruption. Although home blood pressure monitoring is recommended to detect masked or white-coat hypertension, longitudinal data on home blood pressure trajectories during therapy remain limited. This multicenter observational pilot study aims to evaluate the association between clinic and home blood pressure in patients with malignant tumors receiving vascular endothelial growth factor inhibitors, and to assess factors associated with blood pressure variability and the feasibility of home monitoring during therapy. Approximately 50 participants are being enrolled. Home blood pressure is measured twice daily throughout the treatment period, and clinical, laboratory, and treatment-related data and patient-reported data are collected at baseline, during therapy, and at follow-up. The primary outcome is the difference between clinic and home blood pressures at multiple time points during and after vascular endothelial growth factor inhibitor therapy. Blood pressure phenotypes will be classified according to clinic and home blood pressure thresholds, and their clinical characteristics will be compared. Longitudinal trajectory of home blood pressure will be assessed to explore patterns associated with clinical outcomes. This study will clarify the relationship between clinic and home blood pressure, explore factors influencing blood pressure variability, and provide preliminary evidence on the feasibility and clinical value of home blood pressure monitoring in patients receiving angiogenesis inhibitor therapy.

Indexed as

Angiogenesis InhibitorsBlood PressureBlood Pressure Monitoring, AmbulatoryHypertensionNeoplasmsAdultFeasibility StudiesFemaleHumansMaleMiddle AgedPilot ProjectsVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor AAngiogenesis inhibitors therapyDigital hypertensionImplemental hypertensionMorning hypertensionOnco-hypertension

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.